Fredun Pharmaceuticals (539730) Q2 25/26 earnings summary

Executive summary

• Expanded into nutraceuticals, cosmeceuticals, animal healthcare, and mobility, with presence in India and 52 international markets.

• Board approved unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2025.

• Financials reviewed by the Audit Committee and received an unmodified limited review report from statutory auditors.

• Over 1,200 products under registration and 697 approved globally; manufacturing expansion underway.

• Strategic acquisitions in pet care and technology platforms to build a connected pet wellness ecosystem.

Financial highlights

• Q2 FY26 total income: INR 145.29 crore, up 35% year-on-year; EBITDA: INR 22.34 crore, up 60%, margin at 15.37%.

• H1 FY26 total income: INR 265.15 crore, up 42%; EBITDA: INR 39.33 crore, up 61%; PAT: INR 16.50 crore, up 96%.

• Standalone revenue for H1 FY26 was ₹26,298.82 lakhs, up from ₹18,442.77 lakhs in H1 FY25.

• Standalone net profit for H1 FY26 was ₹1,649.81 lakhs, compared to ₹840.32 lakhs in H1 FY25.

• Operating cash flows turned positive, reflecting improved efficiency and profitability.

Outlook and guidance

• By 2029, revenue to be fully driven by vintage generics; by 2032, over 51% from U.S. business.

• Seven-year plan for pet care, five to six years for nutraceuticals, and three years for mobility, with steady, founded growth expected.

• Vintage business expected to grow at 15% CAGR for the next 7-9 years.

• Guidance for INR 90 crore tax for FY2029 remains intact, with conservative approach to projections.

• Results prepared in compliance with Ind AS and reviewed by auditors with no material misstatements noted.